Results 11 to 20 of about 297,289 (305)

Small Dense Low‐Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Elevated plasma levels of direct low‐density lipoprotein cholesterol (LDL‐C), small dense LDL‐C (sdLDL‐C), low‐density lipoprotein (LDL) triglycerides, triglycerides, triglyceride‐rich lipoprotein cholesterol, remnant lipoprotein particle ...
Hiroaki Ikezaki   +5 more
doaj   +1 more source

LDL-Cholesterol-Lowering Therapy [PDF]

open access: yes, 2020
AbstractThe causal relation between elevated levels of LDL-C and cardiovascular disease has been largely established by experimental and clinical studies. Thus, the reduction of LDL-C levels is a major target for the prevention of cardiovascular disease.
Giuseppe Danilo Norata   +2 more
openaire   +3 more sources

Thyroid markers and body composition predict LDL-cholesterol change in lean healthy women on a ketogenic diet: experimental support for the lipid energy model [PDF]

open access: yes, 2023
Introduction: There is a large heterogeneity in LDL-cholesterol change among individuals adopting ketogenic diets. Interestingly, lean metabolically healthy individuals seem to be particularly susceptible, with an inverse association between body mass ...
Cooper, Isabella D.   +8 more
core   +1 more source

Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins [PDF]

open access: yes, 2014
Statins effectively lower LDL cholesterol levels in large studies and the observed interindividual response variability may be partially explained by genetic variation.
Herrington, D.M.   +561 more
core   +1 more source

Mathematical model for low density lipoprotein (LDL) endocytosis by hepatocytes [PDF]

open access: yes, 2008
Individuals with elevated levels of plasma low density lipoprotein (LDL) cholesterol (LDL-C) are considered to be at risk of developing coronary heart disease.
B. O’Malley   +22 more
core   +1 more source

Existing and emerging therapies for the treatment of familial hypercholesterolemia

open access: yesJournal of Lipid Research, 2021
Familial hypercholesterolemia (FH), an autosomal dominant disorder of LDL metabolism that is characterized by elevated LDL-cholesterol, is commonly encountered in patients with atherosclerotic coronary heart disease.
Robert S. Rosenson
doaj   +1 more source

Cholesterol absorption and synthesis related to low density lipoprotein metabolism during varying cholesterol intake in men with different apoE phenotypes.

open access: yesJournal of Lipid Research, 1992
The aim of the present study was, first, to investigate whether cholesterol (C) absorption, enhanced by cholesterol feeding, was related to synthesis of cholesterol, serum level of low density lipoprotein (LDL)-C, and receptor activity for LDL ...
H Gylling, TA Miettinen
doaj   +1 more source

Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans - a quantitative review [PDF]

open access: yes, 2010
Background: Trans fatty acids are produced either by industrial hydrogenation or by biohydrogenation in the rumens of cows and sheep. Industrial trans fatty acids lower HDL cholesterol, raise LDL cholesterol, and increase the risk of coronary heart ...
Wanders Anne J.   +13 more
core   +1 more source

Effects of dietary cholesterol and fatty acids on plasma cholesterol level and hepatic lipoprotein metabolism.

open access: yesJournal of Lipid Research, 1990
The effects of dietary cholesterol and fatty acids on the plasma cholesterol level and rates of very low density lipoprotein (VLDL) cholesterol secretion and low density lipoprotein (LDL) transport through LDL receptors in the liver of the hamster were ...
H Ohtani   +8 more
doaj   +1 more source

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia:Results of a 24week, double-blind, randomized Phase 3 trial [PDF]

open access: yes, 2014
Background:Efficacy and safety of alirocumab were compared with ezetimibe in hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other lipid-lowering therapy. Methods In a Phase 3, randomized, double-blind, double-dummy
Merlet, Laurence   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy